Assessing Blueprint Medicines: Insights From 16 Financial Analysts
Portfolio Pulse from Benzinga Insights
In the past three months, 16 analysts have provided ratings for Blueprint Medicines (NASDAQ:BPMC), with a mix of bullish and bearish perspectives. The average 12-month price target has increased to $115.5, with a high of $168.00 and a low of $75.00. Recent analyst actions include several rating upgrades and price target increases, reflecting positive sentiment towards the company's financial performance and drug pipeline.
June 07, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Blueprint Medicines has received mixed analyst ratings over the past three months, but the average 12-month price target has increased to $115.5. Recent upgrades and positive financial performance, including a 51.87% revenue growth rate and a 92.74% net margin, suggest a positive outlook.
The increase in the average price target and multiple rating upgrades indicate a positive short-term outlook for Blueprint Medicines. The company's strong financial performance, including high revenue growth and net margin, further supports this sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100